Ir para o conteúdo
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • Fevipiprant, a selective prost...
  • Citar
  • Enviar por SMS
  • Enviar por email
  • Imprimir
  • Exportar registo
    • Exportar para RefWorks
    • Exportar para EndNoteWeb
    • Exportar para EndNote
  • Permanent link
Fevipiprant, a selective prostaglandin D-2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by group 2 innate lymphoid cells

Fevipiprant, a selective prostaglandin D-2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by group 2 innate lymphoid cells

Detalhes bibliográficos
Main Authors: Xue, L, Hardman, C, Chen, W, Batty, P, Ogg, G, Erpenbeck, V, Sandham, D
Formato: Conference item
Publicado em: American Thoracic Society 2018
  • Exemplares
  • Descrição
  • Registos relacionados
  • Registo fonte

Registos relacionados

  • Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
    Por: Chen, W, et al.
    Publicado em: (2018)
  • Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
    Por: Sandham, D, et al.
    Publicado em: (2019)
  • Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
    Por: Hardman, C, et al.
    Publicado em: (2019)
  • Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)
    Por: Xue, L, et al.
    Publicado em: (2019)
  • Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
    Por: Veit J. Erpenbeck, et al.
    Publicado em: (2016-12-01)

Opções de Pesquisa

  • Histórico de Pesquisas
  • Pesquisa Avançada

Encontrar Mais

  • Percorrer o Catálogo
  • Percorrer por ordem alfabética
  • Explore Channels
  • Bibliografia Recomendada
  • Novos exemplares

Precisa de ajuda?

  • Dicas de Pesquisa
  • Serviço de Referência
  • FAQs